PRODUCT DETAILS VIEW ALL PRODUCTS

Dibizide Tablets (Glipizide)

  • Each tablet contains Glipizide 5mg.
  • In the treatment of non-insulin dependent diabetes mellitus (NIDDM type-II).
  • The primary mode of action of glipizide is the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets.
  • The recommended starting dose is 5 mg, given before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. or as recommended by physician
  • Contraindicated in patients with known hypersensitivity to the drug.Type 1 diabetes mellitus, Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
  • All sulfonylurea drugs are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemic episodes.
  • There are no adequate and well-controlled studies in human pregnancy, lactation & children.
  • The hypoglycaemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulphonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
  • The most common adverse effects are nausea and diarrhoea, constipation, dizziness, drowsiness, and headache.
  • Anti-Diabetic agents